Journal
NEURON
Volume 62, Issue 4, Pages 479-493Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2009.04.017
Keywords
-
Categories
Funding
- NARSAD
- NIMH [R01 MH068542, 1K99MH083943-01, 5K08MH076083]
- NICHD [5-T32HD55165-02]
- Columbia Lundbeck Translational Fellowship
- Ministere de l'Education Nationale
- l'Enseignement Supenieur et de la Recherche (MENESR, Paris, France)
- Lundbeck Research USA
- AstraZeneca
Ask authors/readers for more resources
Understanding the physiopathology of affective disorders and their treatment relies on the availability of experimental models that accurately mimic aspects of the disease. Here we describe a mouse model of an anxiety/depressive-like state induced by chronic corticosterone treatment. Furthermore, chronic antidepressant treatment reversed the behavioral dysfunctions and the inhibition of hippocampal neurogenesis induced by corticosterone treatment. In corticosterone-treated mice where hippocampal neurogenesis is abolished by X-irradiation, the efficacy of fluoxetine is blocked in some, but not all, behavioral paradigms, suggesting both neurogenesis-dependent and -independent mechanisms of antidepressant action. Finally, we identified a number of candidate genes, the expression of which is decreased by chronic corticosterone and normalized by chronic fluoxetine treatment selectively in the hypothalamus. Importantly, mice deficient in one of these genes, beta-arrestin 2, displayed a reduced response to fluoxetine in multiple tasks, suggesting that beta-arrestin signaling is necessary for the antidepressant effects of fluoxetine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available